Bairui Bio Completes Pre-A Financing Round and Submits IPO Prospectus

Recently, Bairui ShengwuKeji (referred to as "Bairui Bio") completed its Pre-A round of financing. This round of financing was jointly invested by S&C Capital, Norden Ventures, and Ningbo Venture Capital Guidance Fund. The funds will mainly be used to advance the clinical trials, registration applications, and commercialization layout of the company's core product, high-strength absorbable sports medicine products.

Bairui ShengwuKeji, established in 2021 and located in Ningbo, Zhejiang, is committed to building a high-strength absorbable product technology platform. The company’s first product line, absorbable sports medicine products, is currently dominated by imported brands in the Chinese market. Due to issues such as material brittleness and insufficient strength after simple injection molding of absorbable materials, absorbable products often fail clinically due to breakage during implantation, and it is difficult to develop miniature absorbable anchors for small joints. Bairui ShengwuKeji has significantly increased the strength of absorbable sports medicine products using its core technology; some of these products are twice as strong as imported alternatives, effectively addressing the clinical challenges faced by absorbable sports medicine products.